The Readout Loud

Latest Episodes:

Episode 148: Akshay Sharma on gene therapy's setback, biotech's brashest VCs, & the FDA's future Feb 18, 2021

Show notes

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down a significant setback for Bluebird Bio’s gene therapy program with some help from Akshay Sharma, a bone marrow transplant expert at St. Jude Children’s Research Hospital. Then, STAT's Kate Sheridan joins us to discuss her deep dive into Flagship Pioneering, the superlatively successful and frequently grandiose venture firm behind Moderna. Finally, we dig into what the future might hold for a post-Trump FDA, which remains without a permanent commissioner.

Episode 147: David Fajgenbaum on Covid-19 drugs, the state of the pandemic, & meme biotech stocks Feb 11, 2021

Show notes

When will we have enough vaccine doses? How many effective Covid-19 drugs are just waiting to be found? And what do Redditors think about biotech? We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we check in with our colleague Helen Branswell for her view on the current state of the Covid-19 pandemic and the ongoing vaccine rollout. Then, we're joined by David Fajgenbaum, a physician and scientist at the University of Pennsylvania, to talk about his work to identify and develop treatments for people with Covid-19. Lastly, we embark on a lightning round, covering Gilead Sciences' latest setback, a schism in Alzheimer's disease research, and a preview of the newest podcast from STAT.

Episode 146: Paul Offit on vaccine data, 23andMe is going public, & Merck's CEO is retiring Feb 04, 2021

Show notes

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we recap a busy week of news, featuring 23andMe's move to go public through a blank-check company, Merck CEO Ken Frazier's retirement after three decades at the drug maker, and how the future of Biogen’s Alzheimer’s disease drug got a little more complicated. Then, Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, joins us to weigh in on the bounty of recent Covid-19 vaccine data from Johnson & Johnson, Novavax, and AstraZeneca. Finally, STAT's Casey Ross calls in to discuss his investigation into the FDA's chaotic approach to approving medical products that use artificial intelligence.

Episode 145: Kevin Davies on the CRISPR boom, & Megan Ranney on scientific misinformation Jan 28, 2021

Show notes

First, we discuss the implications of Johnson & Johnson’s any-day-now data on a one-shot vaccine for Covid-19. Then, Kevin Davies, executive editor of the CRISPR Journal, joins us to talk about the strange boom in genome editing stocks and the future of the revolutionary technology. Finally, we talk to Megan Ranney, an emergency room physician and Brown University professor, about the challenges of Covid-19 science communication in a post-Trump world.

Episode 144: Remembering STAT's Sharon Begley Jan 22, 2021

Show notes

We're spending this entire episode remembering Sharon Begley, our revered and beloved colleague who died last week from complications of lung cancer. First, STAT's Eric Boodman joins us to discuss Sharon's path-breaking career and what he learned from reporting out her obituary. Then, a trio of STAT editors call in to talk about what it was like to work with Sharon, and we hear from number of her colleagues about what made her a singular writer, mentor, officemate, and friend.

Episode 143: #JPM21: Déjà vu in Alzheimer's research, and OWS's legacy Jan 14, 2021

Show notes

We're devoting this episode to the news coming out of the just-concluded J.P. Morgan Healthcare Conference, the drug industry's largest annual meeting. First, we'll dissect Eli Lilly's surprising data on a new Alzheimer's disease treatment and dig into its implications for the field. Then, we discuss whether there's a bubble inflating in the genome editing world, debate who will run the FDA under a President Biden, and consider the legacy of Moncef Slaoui, the outgoing leader of Operation Warp Speed.

Episode 142: Bob Nelsen on the pandemic's next phase, plus Biden's biopharma plans & a CES preview Jan 07, 2021

Show notes

On this year's first episode, STAT Washington correspondent Lev Facher joins us to break down the implications of a Democrat-controlled Senate. Then, our colleague Erin Brodwin calls in to talk about CES, the massive tech conference taking place next week. Finally, we chat with Bob Nelsen, a biotech venture capitalist and one of the few people who saw the coming pandemic with clarity months before everyone else, about what's ahead in 2021.

Episode 141: Moderna's vaccine milestone, Warp Speed's hurdles, and biotech in 2021 Dec 18, 2020

Show notes

It's the final episode of 2020. We dig into the second vaccine that's been recommended by a panel of FDA advisors, and look ahead to see what's in store for biotech in 2021.

Episode 140: Pfizer's Covid-19 vaccine — the debate, details, and distribution Dec 11, 2020

Show notes

Are Covid-19 vaccines safe for teens? Is the U.S. taking too long to authorize one? And how do you prepare for an FDA grilling?

Episode 139: Angela Rasmussen on AstraZeneca's confusing data, & Adam Koppel on biotech in 2021 Dec 03, 2020

Show notes

Can too much Covid-19 vaccine be a bad thing? Is biotech in a bubble? And how do you make blind mice see again?

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected